Research

Our work focuses on the preclinical development of nanomedicines, which include protein-based self-assembled nanoparticles, and drug-nanoparticle conjugates, for therapy of solid tumors and hematological neoplasias.

All developments pursue their clinical translation and their transfer to the Biotech and Pharma industry. We especially target cancer stem cells that overexpress the chemokine receptor CXCR4, using a targeted drug delivery approach that selectively eliminates these cells, leading to a blockade of metastatic dissemination. Depending on the tumor type, we chemically conjugate small drugs or toxins, or incorporate cytotoxic polypeptides as payloads, to the protein nanocarrier. Using this strategy, we have demonstrated potent prevention of metastasis development and regression of established metastases in colorectal cancer models. We also demonstrated a potent blockade of dissemination in acute myeloid leukemia and diffuse large B-cell lymphoma models.